Universal Beteiligungs und Servicegesellschaft mbH Buys 6,991 Shares of ResMed Inc. $RMD

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in ResMed Inc. (NYSE:RMD) by 7.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,526 shares of the medical equipment provider’s stock after buying an additional 6,991 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.07% of ResMed worth $27,243,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SJS Investment Consulting Inc. grew its position in ResMed by 1,433.3% in the third quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 86 shares in the last quarter. WFA of San Diego LLC bought a new stake in ResMed during the second quarter worth about $26,000. GoalVest Advisory LLC purchased a new position in shares of ResMed in the 3rd quarter worth about $37,000. Harbour Investments Inc. increased its position in shares of ResMed by 264.2% during the 2nd quarter. Harbour Investments Inc. now owns 244 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 177 shares during the last quarter. Finally, Root Financial Partners LLC bought a new position in shares of ResMed during the 3rd quarter valued at about $64,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In related news, Director Witte Jan De sold 2,055 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total transaction of $524,025.00. Following the completion of the transaction, the director owned 4,261 shares in the company, valued at $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total value of $497,660.00. Following the completion of the sale, the director directly owned 66,773 shares of the company’s stock, valued at $16,615,125.59. The trade was a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 21,594 shares of company stock valued at $5,403,495 in the last 90 days. Insiders own 0.65% of the company’s stock.

ResMed Stock Down 1.5%

Shares of NYSE RMD opened at $255.32 on Friday. The firm’s fifty day moving average is $249.81 and its 200 day moving average is $263.21. ResMed Inc. has a 52 week low of $199.92 and a 52 week high of $293.81. The company has a quick ratio of 2.13, a current ratio of 2.89 and a debt-to-equity ratio of 0.07. The company has a market cap of $37.26 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 1.74 and a beta of 0.88.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter last year, the firm earned $2.20 EPS. The company’s revenue was up 9.1% on a year-over-year basis. On average, equities research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, November 13th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Thursday, November 13th. ResMed’s payout ratio is currently 24.56%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RMD. KeyCorp upped their target price on ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Robert W. Baird reissued a “neutral” rating and set a $275.00 price target (down from $300.00) on shares of ResMed in a research note on Tuesday, December 16th. Mizuho lowered their price objective on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Stifel Nicolaus reduced their target price on shares of ResMed from $270.00 to $260.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Finally, UBS Group reiterated a “buy” rating and issued a $345.00 target price on shares of ResMed in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $296.09.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.